ライフサイエンスコーパス: AF

1 AF diagnosed after stroke is an important hallmark of re

2 AF genetic risk was also associated with cardioembolic s

3 AF is an uncommon primary cause of death in HCM virtuall

4 AF is associated with specific WMH lesion pattern among

5 Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen r

6 ts with paroxysmal (53%) and new onset (16%) AF than in patients with persistent or permanent AF (71%

7 The authors performed a GWAS of 14,255 AF cases and 374,939 controls, using whole-genome sequen

8 ociation studies have identified at least 30 AF loci, but the mechanisms through which individual var

9 enome-wide association study (GWAS) of 6,337 AF individuals and 61,607 AF-free individuals from Norwa

10 dy (GWAS) of 6,337 AF individuals and 61,607 AF-free individuals from Norway, including replication i

11 arch Database" in Taiwan, a total of 352,656 AF and 352,656 non-AF patients without antecedent SCD/VA

12 ncluding replication in an additional 30,679 AF individuals and 278,895 AF-free individuals.

13 additional 30,679 AF individuals and 278,895 AF-free individuals.

14 The primary end point was adjudicated AF lasting 6 or more minutes and was assessed at 18 mont

15 istance from center of anus to clitoris; AGD-AF: distance from center of anus to fourchette).

16 Although AF anatomy has been related to linguistic skills, an exp

17 AF was substantially lower in the Americas (AF, 12.2 [95% CI, 8.9-15.6]), based on samples from a co

18 about how diabetes influences outcomes among AF patients.

19 a-analyzed estimate between observed BMI and AF (age- and sex-adjusted hazard ratio 1.05 [1.04-1.06]

20 rd ratio for the association between BMI and AF.

21 romboembolic events, heart failure (HF), and AF progression.

22 s for the association of body mass index and AF (hazard ratio per standard deviation increase, 1.18;

23 ultivariate analysis revealed female sex and AF type prior to the procedure as predictors for AF recu

24 e association between treating specialty and AF outcomes among patients newly diagnosed with AF.

25 e association between treating specialty and AF outcomes.

26 bipolar EGM voltages obtained during SR and AF.

27 tcomes included symptoms, health status, and AF treatment, as well as 2-year risk of death, hospitali

28 omes were induction of type VII collagen and AFs at the test sites and safety assessment.

29 mutations and induces type VII collagen and AFs in RDEB patients.

30 ted net clinical benefit for anticoagulating AF patients with CHA2DS2-VASc scores of 1 or 2.

31 We ascertained AF based on self-report, medical record billing codes, p

32 red with the corresponding autofluorescence (AF) images at 488 nm (SW-AF) and at 787 nm (NIR-AF).

33 We found no significant association between AF and incident colorectal cancer, but we did see a 19%

34 have shown evidence of associations between AF and breast or colorectal cancer, but there have been

35 We examined associations between AF genetic risk scores and ischemic stroke in a separate

36 n with right heart remodeling differ between AF-TR and left-sided heart disease-TR.

37 There was no interaction between AF and exercise training on measures of functional statu

38 This suggests that the link between AF and brain injury extends beyond thromboembolic compli

39 PA analogues bisphenol S (BPS) and bisphenol AF (BPAF) in production of consumer products; however, i

40 als with a first-degree relative affected by AF had a relative risk of 1.92 (95% CI, 1.84-1.99) for A

41 AF with a first-degree relative affected by AF.

42 However, detailed analyses by AF pattern have not been reported.

43 e 2.8 years median follow-up and compared by AF pattern.

44 s shown that the hemodynamic perturbation by AF considered led to substantial increase in stroke prop

45 es while the changes in stroke propensity by AF are negligible for higher curvature angle >90 degrees

46 here are several major mechanisms that cause AF in patients, including a genetic predisposition to de

47 diagnostic accuracy in patients with chronic AF, with a diagnostic performance similar to that in pat

48 D, but without a prior diagnosis of clinical AF.

49 ctrocardiographic monitors (St. Jude CONFIRM-AF) in patients >/=65 years of age attending cardiovascu

50 ncluding a genetic predisposition to develop AF.

51 alent AF (n = 29) at baseline, 117 developed AF during the 20-year follow-up period (incidence rate,

52 ched control subjects, 654 and 328 developed AF, respectively.

53 ars, 1 of 12 patients with CHD had developed AF, and 1 of 10 patients with CHD with AF had developed

54 rs, 1,580 or 13.5% of participants developed AF.

55 However, the risk of developing AF and the complications associated with AF in children

56 The risk of developing AF was 21.99 times higher (95% confidence interval, 19.2

57 ] age, 57.9 [9.2] years) had newly diagnosed AF with a first-degree relative affected by AF.

58 o-terminal transcriptional activation domain AF-1, which has not been targeted for degradation previo

59 PPARalpha N-terminal transactivation domain (AF-1) thereby masking the TAK1 kinase domain.

60 haracteristics that are biologically driving AF risk, and recent studies suggest that fat carries lim

61 riod, the rate of inpatient mortality during AF hospitalization decreased by 4% per year, and the rat

62 in Patients With Atrial Fibrillation [ENGAGE AF-TIMI 48]; NCT00781391).

63 In ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor

64 sistent or long-standing persistent], and ER-AF = early recurrent AF), had better predictive ability

65 Established AF loci only explain a moderate proportion of disease ri

66 ular Risk Assessment in Europe), we examined AF incidence, its association with mortality, common ris

67 achieved both standing [acceleration factor (AF): 0.93; 95% CI: 0.87, 0.99] and walking (AF: 0.93; 95

68 d in the strength of the arcuate fasciculus (AF), a fiber pathway interlinking the left-hemispheric l

69 al cortex) by way of the arcuate fasciculus (AF).

70 c electrograms to guide atrial fibrillation (AF) ablation has yielded conflicting results.

71 ring prevents recurrent atrial fibrillation (AF) after catheter ablation in patients with AF and a hi

72 (VKAs) in patients with atrial fibrillation (AF) and coexisting valvular heart disease (VHD) is of su

73 Atrial fibrillation (AF) and left ventricular systolic dysfunction (LVSD) fre

74 Atrial fibrillation (AF) and stroke are important major health problems that

75 Both obesity and atrial fibrillation (AF) are increasing in epidemic proportions, and both inc

76 med to be vulnerable to atrial fibrillation (AF) as a result of residual shunts, anomalous vessel ana

77 uation in patients with atrial fibrillation (AF) by using invasive coronary angiography (ICA) as the

78 nalysis of contemporary atrial fibrillation (AF) cohorts showed an association between digoxin and in

79 obability of developing atrial fibrillation (AF) considering genetic predisposition and clinical risk

80 patients with extended atrial fibrillation (AF) duration and persistent/long-standing persistent AF.

81 Atrial fibrillation (AF) has been reported as a strong independent risk facto

82 heart failure (HF) and atrial fibrillation (AF) have higher circulating levels of NT-proBNP (N-termi

83 Atrial fibrillation (AF) is a common arrhythmia.

84 Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by

85 Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associa

86 Whether the pattern of atrial fibrillation (AF) modifies the risk/benefit of anticoagulation is cont

87 y of anticoagulation in atrial fibrillation (AF) patients, reflected by time in therapeutic range (TT

88 ause of mortality among atrial fibrillation (AF) patients.

89 ociated with drivers of atrial fibrillation (AF) risk, including left ventricular and pulmonary patho

90 sk factors to influence atrial fibrillation (AF) risk.

91 n of MetS is related to atrial fibrillation (AF) risks.

92 on the rising burden of atrial fibrillation (AF) since the turn of the millennium.

93 chy-arrhytmias, such as atrial fibrillation (AF), are characterised by irregular electrical activity

94 bolism in patients with atrial fibrillation (AF), but less is known about how diabetes influences out

95 Atrial fibrillation (AF), the most common sustained arrhythmia in hypertrophi

96 EAT) is associated with atrial fibrillation (AF), the most frequent cardiac arrhythmia.

97 g mechanisms underlying atrial fibrillation (AF), with the spatial resolution of data often cited as

98 links inflammation and atrial fibrillation (AF).

99 -perpetuating nature of atrial fibrillation (AF).

100 target for treatment of atrial fibrillation (AF).

101 The annulus fibrosus (AF) represents a complex, multilamellar, hierarchical st

102 Ds, 3 trials will assess the time to a first AF diagnosis among patients receiving a CIED for purpose

103 antigen concentrations in WT amniotic fluid (AF) were higher than in IgG-free AF of B cell-deficient

104 k factor for atrial fibrillation or flutter (AF).

105 2%, 17%) for OIS, 3% (95% CI: 0.4%, 19%) for AF, and 1% (95% CI: 0.3%, 4.1%) for CRAO.

106 elative risk of 1.92 (95% CI, 1.84-1.99) for AF.

107 pectively enrolled 105 patients admitted for AF ablation.

108 Adjusted rates of hospitalization for AF increased by approximately 1% per year between 1999 a

109 nd we evaluated rates of hospitalization for AF, in-hospital mortality, length of stay, and hospital

110 .0001) and increases in hospitalizations for AF/supraventricular tachycardia (HR: 1.38; 95% CI: 1.35

111 of lifestyle and risk factor management for AF as upstream noninvasive therapy.

112 utive patients undergoing source mapping for AF.

113 ype prior to the procedure as predictors for AF recurrence.

114 illation has become an important therapy for AF; however, recurrence rates remain high.

115 d with improved rates of overall OAC use for AF, but significant gaps remain.

116 otic fluid (AF) were higher than in IgG-free AF of B cell-deficient dams.

117 On follow-up, freedom from AF after a single FIRM procedure for the entire series w

118 primary efficacy end point was freedom from AF between 90 and 365 days after a single ablation.

119 polar EGMs can extract maximal voltages from AF signals which are not influenced by directional facto

120 ic neuropathy (NA-AION) and amaurosis fugax (AF).

121 e magnitude of HDM or Aspergillus fumigatus (AF) extract-induced airway hyperresponsiveness (AHR), ai

122 ersity among neurons in the anterior fundus (AF) face patch, combining whole-brain fMRI with longitud

123 nts with baseline rhythm data, 382 (17%) had AF, 1,602 (70%) had sinus rhythm, and 308 (13%) had "oth

124 oagulation prescribed at baseline and having AF first diagnosed >7 days post-stroke (late AF) was hig

125 low heart rate may be associated with higher AF risk.

126 are a valuable experimental model for human AF pathophysiology.

127 nd ion channel modulators, relevant in human AF.

128 r after onset of ocular condition was 52% in AF, 22% in OIS, 22% in BRAO, 21% in CRAO, and 6% in NA-A

129 e recommendations for oral anticoagulants in AF are based on the CHA2DS2-VASc stroke risk point score

130 vWF acts as a simple prognostic biomarker in AF and, whilst its addition to current scores statistica

131 Sex differences in AF epidemiology are insufficiently understood.

132 erty of the atrial secretome was enhanced in AF patients.

133 miological studies have shown an increase in AF prevalence in the developed world associated with an

134 spective, real-world, multicenter, PREFER in AF (European Prevention of thromboembolic events-Europea

135 nts (DOACs) may improve overall OAC rates in AF patients, but a large-scale evaluation of their effec

136 ic expansion but not population structure in AF biota.

137 ve Evaluation and Assessment of Therapies in AF) study from the Veterans Health Administration, patie

138 The increased risk of SCD/VAs in AF patients was consistently observed in different age s

139 han right ventricular end-systolic volume in AF-TR (P<0.001).

140 m(2) per 1-U increase, P<0.001) and incident AF (FTO, hazard ratio, 1.07 [1.02-1.11] per A-allele, P=

141 association between fT4 levels and incident AF.

142 evious stroke, and anticoagulation, incident AF patients with vs without an affected first-degree rel

143 ated with a meaningful reduction in incident AF or AFL among older adults with a history of hypertens

144 ted with a significant reduction in incident AF/AFL.

145 e associated with increased risk of incident AF.

146 sk of an alcohol abuse diagnosis on incident AF, MI, and CHF.

147 ained significantly associated with incident AF after additional adjustment for lung function (P=0.02

148 and five CpGs were associated with incident AF after correction for multiple testing (FDR < 0.05).

149 Subjects with incident AF had a 3.5-fold risk of death in comparison with those

150 terol was inversely associated with incident AF with a greater risk reduction in women (hazard ratio

151 hat modify the atrial substrate and increase AF susceptibility.

152 AF first diagnosed >7 days post-stroke (late AF) was highly associated with recurrent stroke/TIA (haz

153 n 70% of patients, but decreased with longer AF duration.

154 rial rotors and focal sources in maintaining AF in diverse populations.

155 onal enrichment analyses suggested that many AF-associated genetic variants act through a mechanism o

156 age, 66+10 years) with persistent AF (median AF history, 14 months; Q1-Q3, 7-36 months) underwent pul

157 images at 488 nm (SW-AF) and at 787 nm (NIR-AF).

158 aiwan, a total of 352,656 AF and 352,656 non-AF patients without antecedent SCD/VAs were identified.

159 Successful ablation for nonparoxysmal AF is challenging.

160 ccess, mostly in patients with nonparoxysmal AF.

161 , patients with newly diagnosed, nonvalvular AF between 2004 and 2012 were identified who had at leas

162 a stronger role in southern-AF than northern-AF, and the synergism between thermal and water-related

163 ed to understand the causal genetic basis of AF.

164 e data of all patients having a diagnosis of AF recorded between January 1996 and December 2013 in th

165 Time to diagnosis of AF was the primary outcome measure.

166 patients with HCM, 304 (20%) had episodes of AF, of which 226 (74%) were confined to symptomatic paro

167 Transient symptomatic episodes of AF, often responsible for impaired quality of life, are

168 Gene expression of AF markers was upregulated with 5-30 folds within the eq

169 visually recognizable electric footprint of AF drivers, for the ablation of all forms of AF.

170 AF drivers, for the ablation of all forms of AF.

171 h acute ischemic stroke and known history of AF admitted from October 2012 through March 2015 to 1622

172 acute ischemic stroke with known history of AF who were not receiving guideline-recommended antithro

173 ntion of obesity may reduce the incidence of AF.

174 R = 1.68, 95% CI: 1.33, 2.12) independent of AF and other confounders.

175 g spatiotemporal dispersion is indicative of AF drivers.

176 ficant reduction of symptoms irrespective of AF.

177 omized studies on the clinical management of AF.

178 in a vernakalant-resistant porcine model of AF.

179 have been explored in preclinical models of AF, and offer potential as a treatment modality with tar

180 -based arrhythmogenicity after the onset of AF.

181 tions and pathways before and after onset of AF.

182 arin was consistent across the 3 patterns of AF.

183 factor modification as the fourth pillar of AF care in conjunction with established pillars of rate

184 nd function, and increases the prevalence of AF, partly related to electroanatomic remodeling in obes

185 hat contribute to the natural progression of AF and may limit the role of Ca(2+) -based arrhythmogeni

186 ss index explained the largest proportion of AF risk.

187 ng patients receiving a CIED for purposes of AF detection.

188 ring 1y-FU in 1687 (45.9%) pts recurrence of AF occurred.

189 rimary outcome was symptomatic recurrence of AF/atrial tachycardia/atrial flutter lasting >30 seconds

190 The lifetime risk of AF >55 years of age was 37.1% and was substantially infl

191 n clinical management of patients at risk of AF and stroke is the focus of the present review paper.

192 e and myocardial infarction increase risk of AF and vice versa creating a feed-forward loop that incr

193 ss were associated with an increased risk of AF in a multiethnic population free of clinical cardiova

194 The prevalence and relative risk of AF in relatives of patients with AF, as well as the rela

195 We estimated the lifetime risk of AF within tertiles of polygenic and clinical risk.

196 tudy the association between HRV and risk of AF.

197 at carries limited or no independent risk of AF.

198 sociated independently with a higher risk of AF; the hazard ratio for each 1 SD lower SD of normal-to

199 xpressed in the pulmonary veins, a source of AF in many individuals.

200 n therapy, commonly used in the treatment of AF, requires spatial information on atrial electrical ex

201 n antiarrhythmic target for the treatment of AF.

202 e conducted a randomized controlled trial of AF screening using an AliveCor Kardia monitor attached t

203 brunch block, Left atrium >/=47 mm, Type of AF [paroxysmal, persistent or long-standing persistent],

204 art failure (HF), but the outcome by type of AF is largely unknown.

205 ) simulations to determine the variations of AF-induced stroke propensity over various image-based pa

206 s over time in the AHA/ACC/HRS guidelines on AF with respect to the distribution of recommendations a

207 New onset AF was associated with increased risk of all outcomes.

208 New onset AF was associated with the greatest risk of adverse outc

209 years, 41 patients (17%) developed new-onset AF.

210 ue (93% and 98%, respectively) for new-onset AF.

211 ) showed good predictive value for new-onset AF.

212 nsgenic mice (TG) leads to spontaneous-onset AF preceded by atrial dilatation and conduction abnormal

213 study included 9,749 patients from the ORBIT-AF (Outcomes Registry for Better Informed Treatment of A

214 d permanent AF, preceded by 7+/-6 paroxysmal AF episodes.

215 74%) were confined to symptomatic paroxysmal AF (average, 5+/-5; range, 1 to >20), whereas 78 (26%) d

216 comparison, control patients with paroxysmal AF and OSA who underwent PV isolation alone without abla

217 tent (4.4%/year; P-adj <0.001) and permanent AF (4.4%/year; P-adj <0.001).

218 o >20), whereas 78 (26%) developed permanent AF, preceded by 7+/-6 paroxysmal AF episodes.

219 han in patients with persistent or permanent AF (71%).

220 ents, and infrequently progress to permanent AF.

221 disease in either sinus rhythm or persistent AF were analyzed using a combined transcriptomic and pro

222 tion and persistent/long-standing persistent AF.

223 men; mean age, 66+10 years) with persistent AF (median AF history, 14 months; Q1-Q3, 7-36 months) un

224 6 European centers, patients with persistent AF were prospectively randomized.

225 ur, particularly in patients with persistent AF.

226 The constructs seeded with porcine AF cells showed approximately 11-, approximately 5.1-, a

227 stry of patients with incident and prevalent AF.

228 Among the 880 participants free of prevalent AF (n = 29) at baseline, 117 developed AF during the 20-

229 were significantly associated with prevalent AF, and five CpGs were associated with incident AF after

230 non-anticoagulated patients with known prior AF.

231 non-anticoagulated patients with known prior AF.

232 Procedural AF termination was achieved in 70% of patients, but decr

233 patient-level meta-analysis with the PROTECT AF trial, are reported with patients in both trials foll

234 ing persistent], and ER-AF = early recurrent AF), had better predictive ability for VLRAF (AUC 0.782)

235 prolonged atrial refractoriness and reduced AF duration without affecting the ventricular refractori

236 In the Africa Region, the rotavirus AF declined from 54.8% (95% CI, 48.3%-61.5%) in rotaviru

237 coagulation, CHADS2 and CHA2DS2-VASc scores, AF diagnosis and timing with respect to the index stroke

238 filtering plays a stronger role in southern-AF than northern-AF, and the synergism between thermal a

239 regarding the value of detecting subclinical AF and of prophylactic therapies are warranted.

240 Observations: Subclinical AF is asymptomatic, short in duration, and usually detec

241 sk may improve identification of subclinical AF or help distinguish between stroke mechanisms.

242 short wavelength fundus autofluorescence (SW-AF).

243 g autofluorescence (AF) images at 488 nm (SW-AF) and at 787 nm (NIR-AF).

244 actor design built with semipermeable Teflon AF-2400 tubes, liquids can be rapidly saturated without

245 moderate, negative correlations between TFS-AF thresholds and audiometric thresholds at low frequenc

246 It is now known that AF genesis requires a vulnerable atrial substrate and th

247 ary care or cardiology within 90 days of the AF diagnosis.

248 nce interval {CI}, 37.6%-44.3%]), though the AF was substantially lower in the Americas (AF, 12.2 [95

249 onextensive and patient-tailored approach to AF ablation.

250 lation for preventing dementia attributed to AF is less established.

251 Other cardiovascular outcomes attributed to AF, including stroke and thromboembolism, are well estab

252 hared and nonshared environmental factors to AF susceptibility.

253 a, and elevated blood pressure predispose to AF, and each factor has been shown to induce structural

254 s posterior to the left atrium is related to AF independent of demographical and cardiovascular risk

255 uggest that in patients with TR secondary to AF, TV annuloplasty should be effective because this ent

256 he contributions of genome-wide variation to AF susceptibility have not been quantified.

257 on for the appropriate intervention to treat AF.

258 Using data from the TREAT-AF (Retrospective Evaluation and Assessment of Therapies

259 the genetic variation and biology underlying AF, we undertook a genome-wide association study (GWAS)

260 ring after stroke could identify undiagnosed AF earlier, leading to appropriate oral anticoagulation

261 (AF): 0.93; 95% CI: 0.87, 0.99] and walking (AF: 0.93; 95% CI: 0.88, 0.98) 7% faster than did infants

262 ained the leading etiology (overall weighted AF, 40.3% [95% confidence interval {CI}, 37.6%-44.3%]),

263 peripheral vascular events, 748 (24.2%) were AF-related.

264 Efforts are warranted to determine whether AF genetic risk may improve identification of subclinica

265 We sought to determine whether AF relates to a distinct WMH lesion pattern which may su

266 CRAO, 127 with BRAO, 80 with OIS and 52 with AF.

267 s (131,441 individuals, including 5,722 with AF).

268 ing AF and the complications associated with AF in children and young adults with CHD have not been c

269 ormed to determine variables associated with AF within 90 days of index hospital discharge.

270 icated multiple genetic loci associated with AF, but the contributions of genome-wide variation to AF

271 d environmental factors were associated with AF, with nonshared environmental factors accounting for

272 loped AF, and 1 of 10 patients with CHD with AF had developed heart failure.

273 pecific symptoms potentially compatible with AF, such as fatigue, dyspnea, and/or palpitations.

274 outcomes among patients newly diagnosed with AF.

275 For mutations with AF around 0.07% in phix174, o2n-seq detects all the muta

276 For the average patient with AF, the threshold of annual ischemic stroke rate where t

277 had no effect on mortality in patients with AF (HR: 0.96, 95% CI: 0.81 to 1.12; p = 0.58) at any hea

278 Of 346 068 patients with AF aged 65+/-12 years, 61% were men and 65% were white.

279 AF) after catheter ablation in patients with AF and a high symptom burden.

280 found in outcome measures for patients with AF and age- and sex-matched patients with HCM without AF

281 ss was significantly larger in patients with AF compared with patients with sinus rhythm: 10.6+/-5.5

282 er cohort study, including 907 patients with AF treated with vitamin K antagonists (3,865 patient-yea

283 VKA monotherapy in patients with AF was associated with a lower risk of first-time MI and

284 spective cohort study of 1,228 patients with AF who underwent late gadolinium enhancement (LGE)-cardi

285 Sc score reclassifies 64.5% of patients with AF with low CHADS2 scores into a class I indication for

286 ive risk of AF in relatives of patients with AF, as well as the relative contributions of heritabilit

287 this cohort of anticoagulated patients with AF, the sole presence of diabetes not requiring insulin

288 ata of LA fibrosis severity in patients with AF.

289 h an increased risk of CVEs in patients with AF.

290 k of invasive breast cancer among those with AF (adjusted hazard ratio (HR) = 1.19, 95% confidence in

291 e 1817 pg/mL (1095-3266 pg/mL) in those with AF and 1271 pg/mL (703-2569 pg/mL) in those without (P<0

292 Women with AF are more symptomatic, present with more atypical symp

293 We categorized patients with and without AF into 5 NT-proBNP bands: <400, 400 to 999 (reference),

294 ng PRRX1 in 962 individuals with and without AF.

295 e- and sex-matched patients with HCM without AF.

296 In N=79 793 individuals without AF diagnosis at baseline (median age, 49.6 years; age ra

297 atriuretic peptide) than HF patients without AF.

298 lues < 0.001, compared with patients without AF.

299 sk of death in comparison with those without AF.

300 Over a median follow-up of 2.6 years, AF was associated with a 24% per year higher rate of mor